Mode
Text Size
Log in / Sign up
N/A N=6 Treatment

Cranial Electrotherapy Stimulation (CES) Therapy

TBI · Anxiety · PTSD · Depression

Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Feb 2018
Primary outcome: Primary: PCL-5 (Post Traumatic Stress Disorder Checklist for the Diagnostic and Statistical Manual of Mental Disorders) for Use in Treating PTSD Symptoms — 44.25 scores on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
CES Therapy (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Male
Sponsor
The University of Texas Health Science Center at San Antonio
Primary completion
May 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
PCL-5 (Post Traumatic Stress Disorder Checklist for the Diagnostic and Statistical Manual of Mental Disorders) for Use in Treating PTSD Symptoms
44.25
PRIMARY
State-Trait Anxiety Inventory (STAI)
81.375
PRIMARY
Beck Depression Inventory (BDI)
25
PRIMARY
TFI (Tinnitus Functional Index)
94.875
PRIMARY
MPAI (Mayo Portland Adaptability Inventory)
48
PRIMARY
WAIS (Wechsler Adult Intelligence Scale) Symbol Search
26.75
PRIMARY
WAIS Coding - Wechsler Adult Intelligence Scale
55.5
SECONDARY
Dizziness- NSI (Neurobehavioral Symptom Inventory)
40.8
SECONDARY
Headache - HIT6 (Headache Impact Test)
62.37
SECONDARY
Sleep - Pittsburgh Sleep Quality Index (PSQI)
10.5

Summary

The primary aim of this proposed study is to gather preliminary data for CES use in treating PTSD and anxiety symptoms in OEF/OIF Veterans with PTSD and a history of TBI.

Eligibility Criteria

Inclusion Criteria

  • Male outpatient, OEF/OIF/OND Veterans diagnosed during the course of clinical care with mild TBI and PTSD, and screened positive for anxiety
  • Good medical health and stable chronic medical conditions.
  • No current alcohol or substance abuse.

Exclusion Criteria

  • Patients with moderate or severe TBI or seizure disorders.
  • Prior CES use
  • Diagnosis of Bipolar Disorder, Schizophrenia, or other psychiatric condition that would require inpatient hospitalization or medical disease that would impair reliable participation in the trial.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02453347). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search